Predicting Tumor Aggressiveness

No two cancers are the same, and it can be difficult to predict which tumors are slow-growing and which are growing quickly. Prognostic tests that look at the level of expression of certain genes in tumors can give you and your healthcare professional additional information about the aggressiveness of your cancer, allowing you to make the most informed decision about your individual treatment plan. Myriad’s Prolaris® for prostate cancer and Myriad myPlan® Lung Cancer are examples of this type of test.

Aggressiveness of Prostate Cancer

Managing localized prostate cancer presents a unique challenge for healthcare professionals due to the highly variable nature of the disease, which makes it difficult to identify those patients with less aggressive, or indolent cancers, from those that have a more aggressive disease. Current clinical tools, such as prostate-specific antigen (PSA) level and Gleason score, provide information on prostate cancer severity, but they do not give an accurate indication of tumor aggressiveness. If you have prostate cancer, learning more about the aggressiveness of your tumor can help you and your healthcare professional make the best treatment decisions for you.*,1,2 Prolaris® has been extensively validated and has been shown to provide the most clinically significant prognostic information at the time of diagnosis.

Learn More About Prolaris

 

Aggressiveness of Early-Stage Lung Cancer

Classification of cancer stage is based primarily on the size and location of the tumor and is an indicator of lung cancer progression. But cancer stage alone does not reveal the aggressiveness of the disease. Since cancer is the uncontrolled and rapid growth of abnormal cells, an aggressive tumor has the potential to grow and spread more rapidly. Knowing how aggressive your cancer is can help you and your healthcare professional feel more confident in the decisions you make about your lung cancer treatment.*Myriad myPlan® Lung Cancer can provide that information.

Learn more about Myriad myPlan Lung Cancer

Prolaris and Myriad myPlan Lung Cancer

Prognostic tests such as Prolaris and Myriad myPlan Lung Cancer can give you and your healthcare professionals accurate information about the aggressiveness of your particular cancer.1-10 These tests analyze the expression of cell proliferation genes in the tumor to measure how fast the cells are dividing. They can be used along with traditional clinical features of cancer progression to determine the risks associated with a patient’s disease, as well as personalize treatment decisions.*

In addition to Prolaris and Myriad myPlan Lung Cancer, Myriad is currently investigating prognostic tests for predicting the aggressiveness of other types of cancer.

*Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professionals.

References

1. Cooperberg MR, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clinical Oncol 2013:31(11):1428-34.

2. Crawford ED, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin 2014 Mar 13 [Epub ahead of print]

3. Freedland SJ, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol, Biol, Phys 2013:86(5):848-853.

4. Wistuba II, Behrens C, Lombardi F, et al. Prognostic Marker in Early Stage Lung Adenocarcinoma. Clinical Cancer Research. November 15, 2013 19:6261-6271

5. Whitfield ML, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2001;13:1977-2000.

6. Cuzick, J, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet 2011: 245-255.

7. Cuzick, J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. British J Cancer 2012:1-5:1095-1099.

8. Bischoff, JT, et al. Prognostic utility of the CCP score generated from biopsy in men treated with prostatectomy. J. Urology 2014 [Epub ahead of print].

9. Bueno R, et al. Validation of a molecular and pathological model for fiver-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 2015; 10:67-73.

10. Rakha E, et al. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. Eur J Cancer 2015; 51:1897-1903